Role of β-adrenergic receptor subtypes in Lipolysis
In vitro lipolysis stimulated by low (-)-isoprenaline concentrations (< or =30 nM) in epididymal white adipocytes from Sprague-Dawley rats was inhibited at least 60-80% by the specific beta1-antagonists LK 204-545 and CGP 20712A (1 microM), suggesting that at these low (10 nM) concentrations of (...
Gespeichert in:
Veröffentlicht in: | Cardiovascular drugs and therapy 2000-12, Vol.14 (6), p.565-577 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 577 |
---|---|
container_issue | 6 |
container_start_page | 565 |
container_title | Cardiovascular drugs and therapy |
container_volume | 14 |
creator | LOUIS, Simon N. S JACKMAN, Graham P NERO, Tracy L IAKOVIDIS, Dimitri LOUIS, William J |
description | In vitro lipolysis stimulated by low (-)-isoprenaline concentrations (< or =30 nM) in epididymal white adipocytes from Sprague-Dawley rats was inhibited at least 60-80% by the specific beta1-antagonists LK 204-545 and CGP 20712A (1 microM), suggesting that at these low (10 nM) concentrations of (-)-isoprenaline lipolysis was primarily (80%) but not solely mediated via beta1-adrenergic receptors. Low concentrations (100 nM) of (-)-noradrenaline and formoterol also confirmed a role for beta1-adrenergic receptors in mediating lipolysis at low concentrations of these agonists. At higher agonist concentrations, beta3-adrenergic receptors were fully activated and were the dominant beta-adrenergic receptor subtype mediating the maximum lipolytic response, and the maximum response was not affected by the beta1-antagonists, demonstrating that the beta3-receptor is capable of inducing maximum lipolysis on its own. Studies of lipolysis induced by the relatively beta2-selective agonist formoterol in the presence of beta1-blockade (1 microM CGP 20712A) demonstrated the inability of the beta2-selective antagonist ICI 118-551 to inhibit the residual lipolysis at concentrations of ICI 118-551 < or = 1 microM. Higher concentrations of ICI 118-551 inhibited the residual formoterol-induced lipolysis competetively, but with low affinity (approximately 500-fold lower than its beta2-adrenergic receptor pA2, 7.80 +/- 0.21), suggesting that formoterol was not acting via beta2-adrenergic receptors. These data are consistent with beta1-adrenergic receptors playing an important role in lipolysis at physiological but not pharmacological concentrations of catecholamines and that beta2-adrenergic receptors play no obvious direct role in mediating beta-adrenergic receptor agonist-induced lipolysis in vitro. Finally, racemic-SR 59230A, unlike the pure (S, S)-isomer (a beta3-selective antagonist), was found to be a nonselective antagonist at the three beta-adrenergic receptor subtypes, showing that the other enantiomers have different selectivity. |
doi_str_mv | 10.1023/A:1007838125152 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72581041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72581041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c281t-692f2fe863a900f241bd2ebf357990aa061161c04b6fd63791a5fdffcfab09cb3</originalsourceid><addsrcrecordid>eNo9z81KxDAUBeAgijOOrt1JQXBXvTdp08bdMPgHBUF0XZL0RiKdtibtYl7LB_GZLDi6upuPc85l7BzhGoGLm_UtAhSlKJHnmPMDtsS8EGnBMzxkS1AcUsFBLthJjB8wU6XKY7ZAFAAiL5Yse-lbSnqXfH-lugnUUXj3NglkaRj7kMTJjLuBYuK7pPJD3-6ij6fsyOk20tn-rtjb_d3r5jGtnh-eNusqtbzEMZWKO-6olEIrADdvMg0n4-ZipUBrkIgSLWRGukaKQqHOXeOcddqAskas2NVv7hD6z4niWG99tNS2uqN-inXB8xIhwxle7OFkttTUQ_BbHXb1358zuNwDHa1uXdCd9fHfKRRSCfEDo8ZhEA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72581041</pqid></control><display><type>article</type><title>Role of β-adrenergic receptor subtypes in Lipolysis</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>LOUIS, Simon N. S ; JACKMAN, Graham P ; NERO, Tracy L ; IAKOVIDIS, Dimitri ; LOUIS, William J</creator><creatorcontrib>LOUIS, Simon N. S ; JACKMAN, Graham P ; NERO, Tracy L ; IAKOVIDIS, Dimitri ; LOUIS, William J</creatorcontrib><description>In vitro lipolysis stimulated by low (-)-isoprenaline concentrations (< or =30 nM) in epididymal white adipocytes from Sprague-Dawley rats was inhibited at least 60-80% by the specific beta1-antagonists LK 204-545 and CGP 20712A (1 microM), suggesting that at these low (10 nM) concentrations of (-)-isoprenaline lipolysis was primarily (80%) but not solely mediated via beta1-adrenergic receptors. Low concentrations (100 nM) of (-)-noradrenaline and formoterol also confirmed a role for beta1-adrenergic receptors in mediating lipolysis at low concentrations of these agonists. At higher agonist concentrations, beta3-adrenergic receptors were fully activated and were the dominant beta-adrenergic receptor subtype mediating the maximum lipolytic response, and the maximum response was not affected by the beta1-antagonists, demonstrating that the beta3-receptor is capable of inducing maximum lipolysis on its own. Studies of lipolysis induced by the relatively beta2-selective agonist formoterol in the presence of beta1-blockade (1 microM CGP 20712A) demonstrated the inability of the beta2-selective antagonist ICI 118-551 to inhibit the residual lipolysis at concentrations of ICI 118-551 < or = 1 microM. Higher concentrations of ICI 118-551 inhibited the residual formoterol-induced lipolysis competetively, but with low affinity (approximately 500-fold lower than its beta2-adrenergic receptor pA2, 7.80 +/- 0.21), suggesting that formoterol was not acting via beta2-adrenergic receptors. These data are consistent with beta1-adrenergic receptors playing an important role in lipolysis at physiological but not pharmacological concentrations of catecholamines and that beta2-adrenergic receptors play no obvious direct role in mediating beta-adrenergic receptor agonist-induced lipolysis in vitro. Finally, racemic-SR 59230A, unlike the pure (S, S)-isomer (a beta3-selective antagonist), was found to be a nonselective antagonist at the three beta-adrenergic receptor subtypes, showing that the other enantiomers have different selectivity.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1023/A:1007838125152</identifier><identifier>PMID: 11300357</identifier><identifier>CODEN: CDTHET</identifier><language>eng</language><publisher>Dordrecht: Springer</publisher><subject>Adipocytes - drug effects ; Adipocytes - metabolism ; Adrenergic beta-Agonists - pharmacology ; Adrenergic beta-Antagonists - pharmacology ; Animals ; Biological and medical sciences ; Cell receptors ; Cell structures and functions ; Dose-Response Relationship, Drug ; Female ; Fundamental and applied biological sciences. Psychology ; Heart Rate - drug effects ; In Vitro Techniques ; Lipolysis - physiology ; Male ; Molecular and cellular biology ; Monoamines receptors (catecholamine, serotonine, histamine, acetylcholine) ; Rats ; Rats, Sprague-Dawley ; Receptors, Adrenergic, beta - physiology ; Receptors, Adrenergic, beta-1 - physiology ; Receptors, Adrenergic, beta-2 - physiology ; Receptors, Adrenergic, beta-3 - physiology ; Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</subject><ispartof>Cardiovascular drugs and therapy, 2000-12, Vol.14 (6), p.565-577</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c281t-692f2fe863a900f241bd2ebf357990aa061161c04b6fd63791a5fdffcfab09cb3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=913693$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11300357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LOUIS, Simon N. S</creatorcontrib><creatorcontrib>JACKMAN, Graham P</creatorcontrib><creatorcontrib>NERO, Tracy L</creatorcontrib><creatorcontrib>IAKOVIDIS, Dimitri</creatorcontrib><creatorcontrib>LOUIS, William J</creatorcontrib><title>Role of β-adrenergic receptor subtypes in Lipolysis</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><description>In vitro lipolysis stimulated by low (-)-isoprenaline concentrations (< or =30 nM) in epididymal white adipocytes from Sprague-Dawley rats was inhibited at least 60-80% by the specific beta1-antagonists LK 204-545 and CGP 20712A (1 microM), suggesting that at these low (10 nM) concentrations of (-)-isoprenaline lipolysis was primarily (80%) but not solely mediated via beta1-adrenergic receptors. Low concentrations (100 nM) of (-)-noradrenaline and formoterol also confirmed a role for beta1-adrenergic receptors in mediating lipolysis at low concentrations of these agonists. At higher agonist concentrations, beta3-adrenergic receptors were fully activated and were the dominant beta-adrenergic receptor subtype mediating the maximum lipolytic response, and the maximum response was not affected by the beta1-antagonists, demonstrating that the beta3-receptor is capable of inducing maximum lipolysis on its own. Studies of lipolysis induced by the relatively beta2-selective agonist formoterol in the presence of beta1-blockade (1 microM CGP 20712A) demonstrated the inability of the beta2-selective antagonist ICI 118-551 to inhibit the residual lipolysis at concentrations of ICI 118-551 < or = 1 microM. Higher concentrations of ICI 118-551 inhibited the residual formoterol-induced lipolysis competetively, but with low affinity (approximately 500-fold lower than its beta2-adrenergic receptor pA2, 7.80 +/- 0.21), suggesting that formoterol was not acting via beta2-adrenergic receptors. These data are consistent with beta1-adrenergic receptors playing an important role in lipolysis at physiological but not pharmacological concentrations of catecholamines and that beta2-adrenergic receptors play no obvious direct role in mediating beta-adrenergic receptor agonist-induced lipolysis in vitro. Finally, racemic-SR 59230A, unlike the pure (S, S)-isomer (a beta3-selective antagonist), was found to be a nonselective antagonist at the three beta-adrenergic receptor subtypes, showing that the other enantiomers have different selectivity.</description><subject>Adipocytes - drug effects</subject><subject>Adipocytes - metabolism</subject><subject>Adrenergic beta-Agonists - pharmacology</subject><subject>Adrenergic beta-Antagonists - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Cell receptors</subject><subject>Cell structures and functions</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Heart Rate - drug effects</subject><subject>In Vitro Techniques</subject><subject>Lipolysis - physiology</subject><subject>Male</subject><subject>Molecular and cellular biology</subject><subject>Monoamines receptors (catecholamine, serotonine, histamine, acetylcholine)</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptors, Adrenergic, beta - physiology</subject><subject>Receptors, Adrenergic, beta-1 - physiology</subject><subject>Receptors, Adrenergic, beta-2 - physiology</subject><subject>Receptors, Adrenergic, beta-3 - physiology</subject><subject>Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9z81KxDAUBeAgijOOrt1JQXBXvTdp08bdMPgHBUF0XZL0RiKdtibtYl7LB_GZLDi6upuPc85l7BzhGoGLm_UtAhSlKJHnmPMDtsS8EGnBMzxkS1AcUsFBLthJjB8wU6XKY7ZAFAAiL5Yse-lbSnqXfH-lugnUUXj3NglkaRj7kMTJjLuBYuK7pPJD3-6ij6fsyOk20tn-rtjb_d3r5jGtnh-eNusqtbzEMZWKO-6olEIrADdvMg0n4-ZipUBrkIgSLWRGukaKQqHOXeOcddqAskas2NVv7hD6z4niWG99tNS2uqN-inXB8xIhwxle7OFkttTUQ_BbHXb1358zuNwDHa1uXdCd9fHfKRRSCfEDo8ZhEA</recordid><startdate>20001201</startdate><enddate>20001201</enddate><creator>LOUIS, Simon N. S</creator><creator>JACKMAN, Graham P</creator><creator>NERO, Tracy L</creator><creator>IAKOVIDIS, Dimitri</creator><creator>LOUIS, William J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20001201</creationdate><title>Role of β-adrenergic receptor subtypes in Lipolysis</title><author>LOUIS, Simon N. S ; JACKMAN, Graham P ; NERO, Tracy L ; IAKOVIDIS, Dimitri ; LOUIS, William J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c281t-692f2fe863a900f241bd2ebf357990aa061161c04b6fd63791a5fdffcfab09cb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adipocytes - drug effects</topic><topic>Adipocytes - metabolism</topic><topic>Adrenergic beta-Agonists - pharmacology</topic><topic>Adrenergic beta-Antagonists - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Cell receptors</topic><topic>Cell structures and functions</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Heart Rate - drug effects</topic><topic>In Vitro Techniques</topic><topic>Lipolysis - physiology</topic><topic>Male</topic><topic>Molecular and cellular biology</topic><topic>Monoamines receptors (catecholamine, serotonine, histamine, acetylcholine)</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptors, Adrenergic, beta - physiology</topic><topic>Receptors, Adrenergic, beta-1 - physiology</topic><topic>Receptors, Adrenergic, beta-2 - physiology</topic><topic>Receptors, Adrenergic, beta-3 - physiology</topic><topic>Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LOUIS, Simon N. S</creatorcontrib><creatorcontrib>JACKMAN, Graham P</creatorcontrib><creatorcontrib>NERO, Tracy L</creatorcontrib><creatorcontrib>IAKOVIDIS, Dimitri</creatorcontrib><creatorcontrib>LOUIS, William J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LOUIS, Simon N. S</au><au>JACKMAN, Graham P</au><au>NERO, Tracy L</au><au>IAKOVIDIS, Dimitri</au><au>LOUIS, William J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of β-adrenergic receptor subtypes in Lipolysis</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2000-12-01</date><risdate>2000</risdate><volume>14</volume><issue>6</issue><spage>565</spage><epage>577</epage><pages>565-577</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><coden>CDTHET</coden><abstract>In vitro lipolysis stimulated by low (-)-isoprenaline concentrations (< or =30 nM) in epididymal white adipocytes from Sprague-Dawley rats was inhibited at least 60-80% by the specific beta1-antagonists LK 204-545 and CGP 20712A (1 microM), suggesting that at these low (10 nM) concentrations of (-)-isoprenaline lipolysis was primarily (80%) but not solely mediated via beta1-adrenergic receptors. Low concentrations (100 nM) of (-)-noradrenaline and formoterol also confirmed a role for beta1-adrenergic receptors in mediating lipolysis at low concentrations of these agonists. At higher agonist concentrations, beta3-adrenergic receptors were fully activated and were the dominant beta-adrenergic receptor subtype mediating the maximum lipolytic response, and the maximum response was not affected by the beta1-antagonists, demonstrating that the beta3-receptor is capable of inducing maximum lipolysis on its own. Studies of lipolysis induced by the relatively beta2-selective agonist formoterol in the presence of beta1-blockade (1 microM CGP 20712A) demonstrated the inability of the beta2-selective antagonist ICI 118-551 to inhibit the residual lipolysis at concentrations of ICI 118-551 < or = 1 microM. Higher concentrations of ICI 118-551 inhibited the residual formoterol-induced lipolysis competetively, but with low affinity (approximately 500-fold lower than its beta2-adrenergic receptor pA2, 7.80 +/- 0.21), suggesting that formoterol was not acting via beta2-adrenergic receptors. These data are consistent with beta1-adrenergic receptors playing an important role in lipolysis at physiological but not pharmacological concentrations of catecholamines and that beta2-adrenergic receptors play no obvious direct role in mediating beta-adrenergic receptor agonist-induced lipolysis in vitro. Finally, racemic-SR 59230A, unlike the pure (S, S)-isomer (a beta3-selective antagonist), was found to be a nonselective antagonist at the three beta-adrenergic receptor subtypes, showing that the other enantiomers have different selectivity.</abstract><cop>Dordrecht</cop><pub>Springer</pub><pmid>11300357</pmid><doi>10.1023/A:1007838125152</doi><tpages>13</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0920-3206 |
ispartof | Cardiovascular drugs and therapy, 2000-12, Vol.14 (6), p.565-577 |
issn | 0920-3206 1573-7241 |
language | eng |
recordid | cdi_proquest_miscellaneous_72581041 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Adipocytes - drug effects Adipocytes - metabolism Adrenergic beta-Agonists - pharmacology Adrenergic beta-Antagonists - pharmacology Animals Biological and medical sciences Cell receptors Cell structures and functions Dose-Response Relationship, Drug Female Fundamental and applied biological sciences. Psychology Heart Rate - drug effects In Vitro Techniques Lipolysis - physiology Male Molecular and cellular biology Monoamines receptors (catecholamine, serotonine, histamine, acetylcholine) Rats Rats, Sprague-Dawley Receptors, Adrenergic, beta - physiology Receptors, Adrenergic, beta-1 - physiology Receptors, Adrenergic, beta-2 - physiology Receptors, Adrenergic, beta-3 - physiology Vertebrates: skin, associated glands, phaneres, light organs, various exocrine glands (salt gland, uropygial gland...), adipose tissue, connective tissue |
title | Role of β-adrenergic receptor subtypes in Lipolysis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T15%3A33%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20%CE%B2-adrenergic%20receptor%20subtypes%20in%20Lipolysis&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=LOUIS,%20Simon%20N.%20S&rft.date=2000-12-01&rft.volume=14&rft.issue=6&rft.spage=565&rft.epage=577&rft.pages=565-577&rft.issn=0920-3206&rft.eissn=1573-7241&rft.coden=CDTHET&rft_id=info:doi/10.1023/A:1007838125152&rft_dat=%3Cproquest_pubme%3E72581041%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72581041&rft_id=info:pmid/11300357&rfr_iscdi=true |